Hereditary nephritis
MONDO:0005334A group of inherited conditions characterized initially by hematuria and slowly progressing to renal insufficiency. The most common form is the Alport syndrome (hereditary nephritis with hearing loss) which is caused by mutations in genes for type IV collagen and defective glomerular basement membrane.
Also known as: hereditary nephritis, familial nephritis, nephritis, familial
151 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New drug OMS721 tested for rare kidney conditions
Disease control TerminatedThis study tested a drug called OMS721 in 31 people with certain kidney diseases, including IgA nephropathy and lupus nephritis. The main goal was to check if the drug is safe and if it reduces protein in the urine, a sign of kidney damage. The study was stopped early, so results…
Phase: PHASE2 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Experimental drug ravulizumab tested for kidney inflammation
Disease control TerminatedThis Phase 2 study tested the drug ravulizumab (Ultomiris) in 123 adults with lupus nephritis or IgA nephropathy, two conditions that cause kidney inflammation. Participants received either ravulizumab or a placebo alongside standard care. The study aimed to see if the drug could…
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Kidney disease drug trial halted midway
Disease control TerminatedThis study tested a drug called OMS721 for people with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage. The trial was stopped early, so results are limited.
Phase: PHASE3 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Kidney disease drug trial halted midway: what happened?
Disease control TerminatedThis study tested a drug called ALXN2050 in people with kidney inflammation caused by lupus (lupus nephritis) or IgA nephropathy. The goal was to see if it could reduce protein in the urine, a sign of kidney damage. About 100 adults were planned to take the drug or a placebo alon…
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental kidney drug for alport syndrome falls short in early trial
Disease control TerminatedThis phase 2 trial tested a weekly injection of lademirsen in 43 adults with Alport syndrome, a genetic condition that damages kidneys. The goal was to see if the drug could slow the decline in kidney function. The study was terminated early, so the results are limited and it's u…
Phase: PHASE2 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 26, 2026 16:08 UTC